News
-
-
-
-
-
-
-
-
PRESS RELEASE
GENFIT: positive late-breaking Phase 2 data for elafibranor in Primary Sclerosing Cholangitis (PSC) to be presented by Ipsen at EASL Congress 2025
GENFIT announces positive Phase 2 data for elafibranor in Primary Sclerosing Cholangitis (PSC) to be presented at EASL Congress 2025 by Ipsen, showing significant efficacy and safety profile improvements -
PRESS RELEASE
GENFIT : les données positives de la Phase 2 évaluant elafibranor dans la Cholangite Sclérosante Primitive (PSC) seront présentées en « late breaking » par Ipsen au congrès de l'EASL 2025
GENFIT annonce les résultats positifs de la Phase 2 sur elafibranor dans la Cholangite Sclérosante Primitive (PSC) à l'EASL 2025 -
PRESS RELEASE
Sparta Capital Ltd. Announces Filing of Annual and Interim Financial Statements and Provides a Corporate Update
Sparta Group (TSXV:SAY) announces filing of annual audited financial statements and interim financial statements. The Company provides updates on strategic partnerships, new CEO, and ongoing nanotechnology testing